Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

NCT07492875 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped New protocol developed

Conditions

Community-Acquired Pneumonia (CAP)
Acute Respiratory Distress Syndrome (ARDS)
Sepsis
Lymphopenia
Immunoparalysis

Interventions

BIOLOGICAL: Nogapendekin alfa inbakicept (NAI)
BIOLOGICAL: agenT-797

Sponsor

ImmunityBio, Inc.